Contrary to the popular belief that antibody development is a bespoke craft, modern methods enable a reproducible, systematic engineering process. This allows for predictable creation of antibodies with specific properties, such as matching affinity for human and animal targets, a feat once considered a "flight of fancy."

A key innovation in Antibody-Drug Conjugates (ADCs) is the 'tandem cleave' linker. This technology requires two separate events—one in the tumor microenvironment and another after internalization—to release the payload, improving stability and reducing systemic toxicity.

To mitigate the severe toxicity of promising pan-RAS inhibitors, companies are adopting antibody-drug conjugate (ADC) technology. This marks a strategic expansion for ADCs, moving beyond traditional cytotoxic chemotherapy payloads to delivering highly specific targeted therapies, aiming to improve the therapeutic window of potent new drug classes.

Despite its current widespread use, experts predict that the traditional method of cysteine engineering for ADC linkers will be phased out. Newer, more precise approaches like enzymatic conjugation and non-canonical amino acids offer superior control over payload attachment and stability, signaling an industry-wide shift toward more advanced and reliable bioconjugation strategies.

The primary reason Antibody-Drug Conjugates (ADCs) stop working is payload resistance, a shift from the traditional belief that failure stems from tumors losing the target antigen. This insight drives development of multi-payload ADCs to overcome this resistance mechanism.

Beyond sheer scale, China's innovation leads in complex, next-generation drug modalities like ADCs and bispecifics. Chinese biotechs now account for roughly one-third of the global Phase 1 and 2 pipelines for these advanced therapies, indicating a shift from iteration on established targets to leadership in new technology platforms.

The modular complexity of Degrader Antibody Conjugates (DACs) is a key challenge. New platform companies like 3C Therapeutics are offering 'plug-and-play' backbones to standardize DAC construction, addressing the problem where attaching an antibody to an existing degrader negatively alters its essential properties.

As multiple effective Antibody-Drug Conjugates (ADCs) become available, the primary clinical challenge is no longer *if* they work, but *how* to use them best. Key unanswered questions involve optimal sequencing, dosing for treatment versus maintenance, and overall length of therapy, mirroring issues already seen in breast cancer.

The differing efficacy and toxicity profiles of TROP2 ADCs like sacituzumab govitecan and Dato-DXD suggest that the drug's linker and payload metabolism are crucial determinants of clinical outcome. This indicates that focusing solely on the target antigen is an oversimplification of ADC design and performance.